

**Supplemental Data; Table 1.** Expanded binding selectivity profile for WAY-163909

Data are percent inhibition average of 2 determinations with 100 nM WAY-163909

<b>NEUTRANSMITTER RELATED</b>	
Adenosine Transporter	18
A1 Adenosine	20
A2 Adenosine	8
? 1A Adrenergic	20
? 1B Adrenergic	6
? 2A Adrenergic	6
? 2B Adrenergic	-11
? 2C Adrenergic	9
? 1 Adrenergic	3
? 2 Adrenergic	15
Peripheral benzodiazepine	7
Dopamine Transporter	-6
D1 Dopamine	5
GABA <sub>A</sub> , agonist site	8
GABA <sub>A</sub> , benzodiazepine site	-18
GABA <sub>B</sub>	18
Glutamate, AMPA site	-2
Glutamate, kainate site	-13
Glutamate, NMDA agonist site	0
Glutamate, NMDA glycine site	3
Glycine, strychnine-sensitive	-6
H1 histamine	15
H2 histamine	14
H3 histamine	18
I2 imidazole, central	-3
Melatonin	3
M1 muscarinic	2
M2 muscarinic	14
M3 muscarinic	-5
M4 muscarinic	-1
M5 muscarinic	5
Nicotinic, a-bungarotoxin site	-7
Norepinephrine Transporter	7
Opiate, delta 1	7
Opiate, kappa	-16
Opiate, mu	7
P2Y purinergic	14
5-HT <sub>1B</sub>	10
5-HT <sub>1D</sub>	6
5-HT <sub>3</sub>	-9

5-HT <sub>4</sub>	21
Sigma 1	11
Sigma 2	-5
<b>ION CHANNELS</b>	
L-Type Calcium Channel, benzothiazepine site	8
L-Type Calcium Channel, dihydropyridine site	-18
N-type Calcium Channel	7
GABA, chloride TBOB site	-14
Glutamate, chloride-dependent site	23
Glutamate, MK-801 site	2
Glutamate, NMDA PCP site	-7
Potassium Channel, ATP-sensitive	4
Potassium Channel, calcium-activated, VI	9
Potassium Channel, calcium-activated, VS	8
Sodium Channel, site 1	17
Sodium Channel, site 2	0
<b>TRANSPORT</b>	
Choline Transport	9
GABA Transport	-6
Glutamate Transport	4
<b>BRAIN/GUT PEPTIDES</b>	
AT1 Angiotensin II	10
AT2 Angiotensin II	8
CCK1, CCK-A	8
CCK2, CCK-B	5
Galanin	1
Neuropeptide Y, non-selective	0
Neurotensin	2
Somatostatin, non-selective	18
VIP, PACAP SV1	13
VIP, non-selective	-23
Vasopressin 1	-1